304 related articles for article (PubMed ID: 23416215)
1. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.
Gao X; Wang W; Li Y; Zhang S; Duan Y; Xing L; Zhao Z; Zhang P; Li Z; Li R; Wang X; Yang P
Antiviral Res; 2013 Apr; 98(1):4-11. PubMed ID: 23416215
[TBL] [Abstract][Full Text] [Related]
2. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
[TBL] [Abstract][Full Text] [Related]
4. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
[TBL] [Abstract][Full Text] [Related]
5. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
[TBL] [Abstract][Full Text] [Related]
7. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
[TBL] [Abstract][Full Text] [Related]
8. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
9. Protection against multiple subtypes of influenza viruses by virus-like particle vaccines based on a hemagglutinin conserved epitope.
Chen S; Zheng D; Li C; Zhang W; Xu W; Liu X; Fang F; Chen Z
Biomed Res Int; 2015; 2015():901817. PubMed ID: 25767809
[TBL] [Abstract][Full Text] [Related]
10. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
[TBL] [Abstract][Full Text] [Related]
11. Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge.
Forqani M; Hosseini SM; Farahmand B; Saleh M; Shokouhi H; Torabi A; Fotouhi F
Biotechnol Lett; 2021 Nov; 43(11):2137-2147. PubMed ID: 34491470
[TBL] [Abstract][Full Text] [Related]
12. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
13. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
Zhao G; Sun S; Du L; Xiao W; Ru Z; Kou Z; Guo Y; Yu H; Jiang S; Lone Y; Zheng BJ; Zhou Y
Virol J; 2010 Jul; 7():151. PubMed ID: 20624292
[TBL] [Abstract][Full Text] [Related]
14. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
[TBL] [Abstract][Full Text] [Related]
15. Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60 protein vaccine construct in BALB/c mice.
Yang P; Wang W; Gu H; Li Z; Zhang K; Wang Z; Li R; Duan Y; Zhang S; Wang X
Antiviral Res; 2014 Nov; 111():1-7. PubMed ID: 25173575
[TBL] [Abstract][Full Text] [Related]
16. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
[TBL] [Abstract][Full Text] [Related]
17. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
18. IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.
Khodamoradi S; Shenagari M; Kheiri MT; Sabahi F; Jamali A; Heidari A; Ashrafkhani B
Arch Virol; 2018 Apr; 163(4):877-886. PubMed ID: 29270718
[TBL] [Abstract][Full Text] [Related]
19. Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
Kim J; Chang J
Vaccine; 2024 May; 42(15):3505-3513. PubMed ID: 38714444
[TBL] [Abstract][Full Text] [Related]
20. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
